Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The competition to enhance CRISPR gene editing technology is intensifying, with a focus on improving the delivery mechanisms for gene editors. Various startups are emerging in this field, with many concentrating on the editing enzymes that facilitate DNA integration. Notably, Kano Therapeutics, co-founded by CEO Fas Engelhardt, is innovating by enhancing the DNA payload itself, aiming to address challenges in gene insertion. Despite some setbacks, industry experts believe that advancements in delivery systems will be achieved, maintaining the momentum of CRISPR technology as a leading solution for gene editing in common diseases.
In the redhot gene insertion field, most new startups are focused on the editing enzymes that integrate DNA. But @fasengelhardt, cofounder and CEO of @kano_tx, is working on improving the DNA payload itself. Read more in my exclusive for @endpts: https://t.co/rnttuTy30d
In the redhot gene insertion field, most new startups are focused on the editing enzymes that integrate DNA. But @fasengelhardt, cofounder and CEO of @kano_tx, is working on improiving the DNA payload itself. Read more in my exclusive for @endpts: https://t.co/rnttuTy30d
🧬 Still the only show in town pioneering gene editing in common disease - speed bump yes. They will overcome the delivery issue. $VERV https://t.co/KkwvchoHbu
